載入中
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
前收盤價
US$8.60
−US$0.41 · -4.55%
盤中時間採用ET。市場資料可能有所延遲。
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
日內區間
目前US$8.60
52週區間
目前US$8.60
盤中時間採用ET。市場資料可能有所延遲。
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
日內區間
目前US$8.60
52週區間
目前US$8.60
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | 1318.5萬 USD | — | 449.01萬 USD | 485.37萬 USD | 146.85萬 USD |
| 銷貨成本 | 6.27萬 USD | — | 9.76萬 USD | 41.85萬 USD | 21.75萬 USD |
| 毛利 | 1312.24萬 USD | — | 439.25萬 USD | 443.52萬 USD | 125.09萬 USD |
| 研究與開發 | 1236.89萬 USD | 1489.85萬 USD | 2240.04萬 USD | 2263.06萬 USD | 2132.74萬 USD |
| 銷售、一般及管理費用 | 948.44萬 USD | 780.93萬 USD | 1227萬 USD | 1529.08萬 USD | 1651.19萬 USD |
| 營業費用 | 2185.33萬 USD | 1745.99萬 USD | 2688.86萬 USD | 3689.41萬 USD | 3783.94萬 USD |
| 利息收入 | 29.71萬 USD | — | — | — | — |
| 利息支出 | 6726 USD | 1.5萬 USD | 1.71萬 USD | 2萬 USD | 2.97萬 USD |
| 折舊和攤銷 | 6.27萬 USD | 25.89萬 USD | 33.91萬 USD | 28.83萬 USD | 12.67萬 USD |
| 營業利益 | −866.83萬 USD | −1745.99萬 USD | −2249.61萬 USD | −3245.89萬 USD | −3658.84萬 USD |
| 淨利 | −837.79萬 USD | −1730.73萬 USD | −2973.61萬 USD | −2403.67萬 USD | −3619.83萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅3項
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
